Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03804424 · ClinicalTrials.gov registry record · Early Phase 1
64Cu-LLP2A for Imaging Multiple Myeloma
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT03804424 is a Early Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 10 participants.
The verdict
NCT03804424, a Early Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The investigators are performing a trial with goals to demonstrate the feasibility of imaging multiple myeloma (MM) patients with 64Cu-LLP2A-positron emission tomography (PET)/magnetic resonance (MR). The investigators suggest that 64Cu-LLP2A will allow for an accurate molecular imaging of MM lesions, which will have an important impact on early stage disease detection and in the long term on the initiation and choice of therapy in these patients.
Interventions
- DEVICE PET/MR
- DRUG 64Cu-LLP2A
- PROCEDURE Urine sample
- PROCEDURE Blood samples for serum stability
- PROCEDURE Blood samples for metabolite analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-11-20 |
| Est. Completion | 2021-10-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03804424
The ClinicalTrials.gov registry entry for NCT03804424 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which PET/MR is the first listed.
NCT03804424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03804424 about?
NCT03804424 is a clinical study titled "64Cu-LLP2A for Imaging Multiple Myeloma". The investigators are performing a trial with goals to demonstrate the feasibility of imaging multiple myeloma (MM) patients with 64Cu-LLP2A-positron emission tomography (PET)/magnetic resonance (MR). The investigators suggest that 64Cu-LLP2A will allow for an accurate molecular imaging of MM lesion...
What is the current status of trial NCT03804424?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2018-11-20. Estimated completion is 2021-10-01.
What interventions are being tested in trial NCT03804424?
The interventions under investigation include: PET/MR (DEVICE), 64Cu-LLP2A (DRUG), Urine sample (PROCEDURE), Blood samples for serum stability (PROCEDURE), Blood samples for metabolite analysis (PROCEDURE).
Who is sponsoring clinical trial NCT03804424?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.